BEEOXAL | Treatment against honeybee varroosis based on highly effective application of oxalic acid through sublimation

Summary
Varroosis is the most serious honeybee disease worldwide, causing €197 million loss yearly in the eight main European beekeeping countries, and severe population decline of this main pollination agent, with strong impact on agriculture and wildlife biodiversity. Negative effects are of such extent that the EU provides specific funding (€33.1 M, 2014-16), to support beekeepers applying compulsory annual anti-varroosis treatments, but current medicaments cannot effectively control varroosis because none, either synthetic of organic, guarantee all the features required for optimal pest control: 1) High efficacy; 2) natural and safe for humans, honeybees and environment; 3) no resistance development; 4) Easy-to-use. BEEOXAL outmatches existing solutions by combining these four features. It consists of a treatment kit with (1) easy-to-use mono-dose pellets and (2) a specifically developed device that burns (sublimates) the tablet so it is spread like a cloud inside the hive. BEEOXAL results from the research and vast field experience of Sagavet Soluciones SL, a Spanish SME delivering animal health solutions. Based on a component already present in honey, oxalic acid, BEEOXAL has an efficacy of 96.8%, a large therapeutic margin thanks to improved spot-on formulation and dosage. Unlike synthetic products, BEEOXAL’s organic nature ensures no residue. The ready-for-use mono-dose pellets do not require mixing or handling, and the burner device to directly sublimate the tablet inside each hive allows a homogeneous distribution of the medicament in 30 seconds (x6 times faster than current treatments). This is crucial since it allows beekeepers to work safely and to avoid under/over doses (secure), maximising overall effectiveness. Backed by its international network (Cenavisa, Byopic), Soluciones Apícolas forecasts €6.8 million cumulative revenue for 2020-2022, and payback of 1 year, while generating 12 new jobs.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/781067
Start date: 01-08-2017
End date: 30-11-2017
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

Varroosis is the most serious honeybee disease worldwide, causing €197 million loss yearly in the eight main European beekeeping countries, and severe population decline of this main pollination agent, with strong impact on agriculture and wildlife biodiversity. Negative effects are of such extent that the EU provides specific funding (€33.1 M, 2014-16), to support beekeepers applying compulsory annual anti-varroosis treatments, but current medicaments cannot effectively control varroosis because none, either synthetic of organic, guarantee all the features required for optimal pest control: 1) High efficacy; 2) natural and safe for humans, honeybees and environment; 3) no resistance development; 4) Easy-to-use. BEEOXAL outmatches existing solutions by combining these four features. It consists of a treatment kit with (1) easy-to-use mono-dose pellets and (2) a specifically developed device that burns (sublimates) the tablet so it is spread like a cloud inside the hive. BEEOXAL results from the research and vast field experience of Sagavet Soluciones SL, a Spanish SME delivering animal health solutions. Based on a component already present in honey, oxalic acid, BEEOXAL has an efficacy of 96.8%, a large therapeutic margin thanks to improved spot-on formulation and dosage. Unlike synthetic products, BEEOXAL’s organic nature ensures no residue. The ready-for-use mono-dose pellets do not require mixing or handling, and the burner device to directly sublimate the tablet inside each hive allows a homogeneous distribution of the medicament in 30 seconds (x6 times faster than current treatments). This is crucial since it allows beekeepers to work safely and to avoid under/over doses (secure), maximising overall effectiveness. Backed by its international network (Cenavisa, Byopic), Soluciones Apícolas forecasts €6.8 million cumulative revenue for 2020-2022, and payback of 1 year, while generating 12 new jobs.

Status

CLOSED

Call topic

SMEInst-11-2016-2017

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.1. Mainstreaming SME support, especially through a dedicated instrument
H2020-SMEINST-1-2016-2017
SMEInst-11-2016-2017 Boosting the potential of small businesses in the areas of climate action, environment, resource efficiency and raw materials
H2020-SMEINST-2-2016-2017
SMEInst-11-2016-2017 Boosting the potential of small businesses in the areas of climate action, environment, resource efficiency and raw materials
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.5. SOCIETAL CHALLENGES - Climate action, Environment, Resource Efficiency and Raw Materials
H2020-EU.3.5.0. Cross-cutting call topics
H2020-SMEINST-1-2016-2017
SMEInst-11-2016-2017 Boosting the potential of small businesses in the areas of climate action, environment, resource efficiency and raw materials
H2020-SMEINST-2-2016-2017
SMEInst-11-2016-2017 Boosting the potential of small businesses in the areas of climate action, environment, resource efficiency and raw materials